A treatment system includes a guide sheath, and a catheter provided with a pressure-controlled element. The pressure-control element preferably includes an expanded configuration adapted to extend across a small feeder vessel branching from the splenic vein. The pressure-control element is positioned with the feeder vessel, and a therapeutic agent is delivered under pressure directly into the feeder vessel, where it is forced to penetrate deep into tissue. Pressure responsive elements for monitoring intravascular pressure are also provided to time delivery of the therapeutic agent for maximum uptake by the target organ. Methods for treating tissues and organs via vascular pathways are provided.

A surgical fluid management system delivers fluid for distending a uterine cavity to allow cutting and extraction of uterine fibroid tissue, polyps and other abnormal uterine tissue. The system comprises a fluid source, fluid deliver lines, one or more pumps, and a filter for re-circulating the distension fluid between the source and the uterine cavity. A controller can monitor fluid retention by the patient.

Catheters are disclosed that are configured for insertion into the vasculature connected to the prostate gland of a male patient or uterus of a female patient. Such catheters may comprise a conduit having one or more bends. Conduits with a general U-shaped bend and a compound curve are within the scope of this disclosure Methods related to the catheters, including methods of use and methods of manufacture, are also disclosed.

The invention encompasses improved catheters comprised of multiple tubular bodies and methods of using them in artificial insemination.

Devices, systems for localized delivery of a chemotherapy, hormonal therapy or targeted drug/biologic therapy to a target tissue area of an internal body organ of a patient. A catheter 10 forms a sealed treatment chamber in a natural lumen extending through the target tissue area. Air is purged from the chamber, which is then filled with a liquid drug solution for an adequate treatment session time, solution volume and drug concentration to saturate the target tissue area, thereby providing the treatment. The liquid drug solution may be circulated or recirculated through the chamber or maintained stationary therewithin. The drug may saturate the target tissue area and pass therethrough into the lymphatic system or interstitial space, which may serve as a reservoir of the drug for continued therapeutic treatment after withdrawal of the catheter. The chamber is evacuated at the end of the treatment session.

An intravaginal device for cervical ripening comprising an inflatable portion and a tube in fluid communication with the inflatable portion. The inflatable portion is configurable between a deflated and an inflated state, and the inflatable portion is configured to be inserted into a vagina when in the deflated state and to ripen a cervix when inflated with fluid. The tube is configurable between an extended state and a retracted state. In the extended state, the tube is configured to be located at least in part outside the vagina to deliver fluid to inflate the inflatable portion. In the retracted state, the tube is configured to be located within the vagina.

A method and system of providing therapy to a patient's uterus is provided, which can include any number of features. The method can include the steps of inserting a uterine device into the uterus and performing a uterine integrity test to determine that the uterus is intact and not perforated. If it is determined that the uterus is not perforated, a patency test can be performed to determine that the uterine device is not clogged or embedded in tissue. If the uterus is intact and the device is not clogged or embedded in tissue, the uterus can be treated with the uterine device, e.g., uterine ablation. Systems for performing these methods are also disclosed.

A process for recovering one or more blastocysts from a uterus of a human is disclose which comprises placing a device transvaginally into a cervical canal of the patient; delivering fluid through the device to the uterus and applying a vacuum to the uterus to aspirate fluid and entrained one or more blastocysts from the uterus; and causing a disruption of to the uterus and/or to one or more embryos remaining in the uterus following removal of one or more blastocysts from the uterus to reduce the chance that any such retained embryos remaining in the uterus will form a viable pregnancy, wherein the causing a disruption comprises one or more of the following: inducing a mechanical disruption of the uterus, delivering a hormonal agent to the uterus, delivering a chemical agent to the uterus, inducing a thermal disruption of the uterus, or using ultrasound or radiofrequency energy to induce said disruption. Kits and uterine lavage systems are further provided for performing the processes described in the invention.

A system for delivering one or more substances into a Fallopian tube of a patient may include a balloon catheter including a tube having a distal end, a balloon having a first end coupled to the distal end of the tube, and a push wire having a distal end coupled to a second end of the balloon, which may be hollow. The balloon may be movable between an inverted position and an everted position. The balloon catheter may be configured to receive the one or more substances such that the one or more substances may be retained by the balloon, or delivered through the push wire, or both. During eversion, or in the everted position, or both, the one or more substances may be delivered into the Fallopian tube.

Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.